Brief: ANI Pharmaceuticals Q3 Adjusted EPS USD 1.27
08/11/2023 11:50
Nov 08 (Reuters) - ANI Pharmaceuticals Q3 revenue USD 131.829 million. * Q3 operating expenses USD 113.881 million * Q3 operating income USD 17.948 million * Q3 net income USD 9.94 million * outlook FY adjusted EPS USD 4.29-4.57 * outlook FY adjusted EBITDA USD 128-133 million
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary